Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense^® 365 CGM system.